Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 800 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: estrogen Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

NCT03740009
View directory record Official record
Conditions
Perimenopausal Disorder, Depression
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

NCT02296801
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Breast Tumors
Interventions
Letrozole, palbociclib
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Decatur, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

NCT02392611
View directory record Official record
Conditions
Solid Tumors and Lymphomas
Interventions
Alobresib, Exemestane, Fulvestrant
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 21, 2026, 5:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

NCT06866119
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

NCT00141557
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 21, 2026, 5:10 PM EDT
Completed No phase listed Observational

Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women

NCT00572858
View directory record Official record
Conditions
Estrogen Deficiency
Interventions
Blood test, Blood test, Ultrasound of neck arteries, Saliva test
Procedure · Genetic
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Up to 55 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

NCT04760691
View directory record Official record
Conditions
HIV, Prophylaxis, Transgender
Interventions
Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

NCT01698918
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 21, 2026, 5:10 PM EDT
Terminated Phase 3 Interventional Results available

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

NCT00968968
View directory record Official record
Conditions
Cancer
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
112
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 21, 2026, 5:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Elacestrant in Advanced Triple Positive Breast Cancer

NCT07612215
View directory record Official record
Conditions
ER Positive, HER2 Positive Breast Cancer
Interventions
Elacestrant, Trastuzumab, Pertuzumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

NCT01928186
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis, Run-in (short pre-surgery course) of endocrine-targeted therapy
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 21, 2026, 5:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
ARV-471, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02213042
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Mobile, Alabama • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Inorganic Nitrate: Sex Differences in Muscle Contractile Function and Efficiency

NCT04588740
View directory record Official record
Conditions
Healthy
Interventions
concentrated beet root juice, Placebo beet root juice
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 34 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

NCT01216176
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, AZD0530 (saracatinib), Placebo
Drug
Lead sponsor
Joyce Marie Slingerland, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

NCT01248416
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 21, 2026, 5:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Boston Migraine and Contraception Study

NCT01216358
View directory record Official record
Conditions
Headache
Interventions
Not listed
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710
View directory record Official record
Conditions
Endometrial Hyperplasia, Osteoporosis
Interventions
Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 21, 2026, 5:10 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

NCT03573648
View directory record Official record
Conditions
Breast Cancer
Interventions
Avelumab, Endocrine therapy, Palbociclib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Completed No phase listed Observational

Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure

NCT04564378
View directory record Official record
Conditions
Fuchs Dystrophy
Interventions
This is an observational study. There is no therapeutic intervention.
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
55 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 5:10 PM EDT
Completed No phase listed Observational Results available

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

NCT05361655
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib + an aromatase inhibitor, Aromatase inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

NCT02003209
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
Drug · Other · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
731
States / cities
Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 5:10 PM EDT